Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 174 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neutrophils Clear all
Withdrawn Phase 1Phase 2 Interventional

MPH966 for Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

NCT03986086
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
MPH966, Placebo
Drug
Lead sponsor
Nelson Chao
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis

NCT00987389
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA)
Interventions
Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose], Glucocorticoids [Reduced Dose]
Procedure · Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 25, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT07176546
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener's, GPA
Interventions
Avacopan, Placebo
Drug
Lead sponsor
Robert Spiera, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Edison, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 4 Interventional

Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT02626845
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions
Rituximab, Placebo
Drug · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Not applicable Interventional Results available

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227
View directory record Official record
Conditions
ANCA Associated Vasculitis
Interventions
ENUMERATION OF CD5+ B Cells
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 22, 2026, 12:02 PM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Bioequivalence of Two Different Forms of Entrectinib (Forms A and C) Under Fasted Conditions in Healthy Subjects

NCT03796013
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Entrectinib Form A, Entrectinib Form C
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunologic Function in the Elderly After Injury

NCT00447135
View directory record Official record
Conditions
Over the Age of 65, Admitted to the Trauma Service
Interventions
Not listed
Lead sponsor
Summa Health System
Other
Eligibility
66 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01750697
View directory record Official record
Conditions
Granulomatosis With Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
6
States / cities
Louisville, Kentucky • Hackensack, New Jersey • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting No phase listed Observational

Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)

NCT04296071
View directory record Official record
Conditions
Lung Injury, Cardiopulmonary Bypass
Interventions
Research study
Other
Lead sponsor
Sophia Koutsogiannaki
Other
Eligibility
Up to 12 Months
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed No phase listed Observational

Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

NCT00315393
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Wegener's
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Jul 22, 2026, 12:02 PM EDT
Completed No phase listed Observational

Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma

NCT02659618
View directory record Official record
Conditions
Severe Persistent Asthma
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
12 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Moderate Fall in eGFR

NCT01136876
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
Iopamidol, Iodixanol-320
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Springfield, Illinois • New Brunswick, New Jersey • Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290
View directory record Official record
Conditions
ANCA Associated Vasculitis (AAV)
Interventions
Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Active, not recruiting Phase 2 Interventional

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions
Iptacopan, Placebo, Rituximab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Mesa, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting No phase listed Observational

One-Time DNA Study for Vasculitis

NCT01241305
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Giant Cell Arteritis, Granulomatosis With Polyangiitis (Wegener's), Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu's Arteritis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
7 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional

Steroids and Methotrexate to Treat Systemic Vasculitis

NCT00001256
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
prednisone and methotrexate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers

NCT00753870
View directory record Official record
Conditions
Healthy Smokers
Interventions
CCRE inhalation
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2011 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting No phase listed Observational

Neutrophil Phenotypic Profiling and Organ Injury Assessment in Patients With Sepsis

NCT04103268
View directory record Official record
Conditions
Sepsis
Interventions
sepsis
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Month to 17 Years
Enrollment
72 participants
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional

Validation of a Low-cost Platelet-Rich Plasma (PRP)

NCT06184048
View directory record Official record
Conditions
Platelet-Rich Plasma (PRP), Knee Osteoarthritis (OA)
Interventions
Intra-Articular knee injection of LC-PRP
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional Results available

Mepolizumab in Episodic Angioedema With Eosinophilia

NCT04128371
View directory record Official record
Conditions
Eosinophilia, Angioedema
Interventions
mepolizumab
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

NCT03712345
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low dose, IFX-1 high dose, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

LCI Apheresis to Obtain Plasma or White Blood Cells

NCT00562601
View directory record Official record
Conditions
Apheresis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Phase 1 Interventional

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

NCT04521764
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein, Computed Tomography, Magnetic Resonance Imaging, Biopsy, Biospecimen Collection
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 12:02 PM EDT